120 related articles for article (PubMed ID: 9152376)
21. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
22. Functional reduction in mu-opioidergic system in the spinal cord under a neuropathic pain-like state following chronic ethanol consumption in the rat.
Narita M; Miyoshi K; Narita M; Suzuki T
Neuroscience; 2007 Feb; 144(3):777-82. PubMed ID: 17156932
[TBL] [Abstract][Full Text] [Related]
23. Morphine-induced antinociception in the formalin test: sensitization and interactions with D1 and D2 dopamine receptors and nitric oxide agents.
Zarrindast MR; Asgari-Afshar A; Sahebgharani M
Behav Pharmacol; 2007 May; 18(3):177-84. PubMed ID: 17426481
[TBL] [Abstract][Full Text] [Related]
24. Effect of mu and kappa opioids on injury-induced microglial accumulation in leech CNS: involvement of the nitric oxide pathway.
Yahyavi-Firouz-Abadi N; Tahsili-Fahadan P; Ostad SN
Neuroscience; 2007 Feb; 144(3):1075-86. PubMed ID: 17169497
[TBL] [Abstract][Full Text] [Related]
25. Influence of ketamine and its interactions with morphine and nalbuphine on the level of enkephalins in some parts of the brain and spinal cord.
Kołada I; Kmieciak-Kołada K; Huzarska M; Dyaczyńska-Herman A; Herman ZS
Pol J Pharmacol; 1994; 46(3):139-46. PubMed ID: 8000445
[TBL] [Abstract][Full Text] [Related]
26. Antiexudative effects of opioids and expression of kappa- and delta-opioid receptors during intestinal inflammation in mice: involvement of nitric oxide.
Jiménez N; Puig MM; Pol O
J Pharmacol Exp Ther; 2006 Jan; 316(1):261-70. PubMed ID: 16183704
[TBL] [Abstract][Full Text] [Related]
27. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics?
Courteix C; Bourget P; Caussade F; Bardin M; Coudore F; Fialip J; Eschalier A
J Pharmacol Exp Ther; 1998 Apr; 285(1):63-70. PubMed ID: 9535995
[TBL] [Abstract][Full Text] [Related]
28. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of intrathecally administered delta and mu opioid receptor agonists on formalin-evoked nociception and on the expression of Fos-like immunoreactivity in the spinal cord of the rat.
Hammond DL; Wang H; Nakashima N; Basbaum AI
J Pharmacol Exp Ther; 1998 Jan; 284(1):378-87. PubMed ID: 9435201
[TBL] [Abstract][Full Text] [Related]
30. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
31. Involvement of N-methyl-D-aspartate receptors and nitric oxide in the rostral ventromedial medulla in modulating morphine pain-inhibitory signals from the periaqueductal grey matter in rats.
Javanmardi K; Parviz M; Sadr SS; Keshavarz M; Minaii B; Dehpour AR
Clin Exp Pharmacol Physiol; 2005 Jul; 32(7):585-9. PubMed ID: 16026519
[TBL] [Abstract][Full Text] [Related]
32. Effect of chronic administration of L-arginine, NG-nitro-L-arginine or their combination on morphine concentration in peripheral tissues and urine of the mouse.
Bian JT; Bhargava HN
Gen Pharmacol; 1998 May; 30(5):753-7. PubMed ID: 9559330
[TBL] [Abstract][Full Text] [Related]
33. Time course of the distribution of morphine in brain regions and spinal cord after intravenous injection to spontaneously hypertensive and normotensive Wistar-Kyoto rats.
Bhargava HN; Villar VM; Rahmani NH; Larsen AK
J Pharmacol Exp Ther; 1992 Jun; 261(3):1008-14. PubMed ID: 1602368
[TBL] [Abstract][Full Text] [Related]
34. Possible mechanisms of action in quercetin reversal of morphine tolerance and dependence.
Naidu PS; Singh A; Joshi D; Kulkarni SK
Addict Biol; 2003 Sep; 8(3):327-36. PubMed ID: 13129835
[TBL] [Abstract][Full Text] [Related]
35. Opioid peptide receptor studies. 17. Attenuation of chronic morphine effects after antisense oligodeoxynucleotide knock-down of RGS9 protein in cells expressing the cloned Mu opioid receptor.
Xu H; Wang X; Wang J; Rothman RB
Synapse; 2004 Jun; 52(3):209-17. PubMed ID: 15065220
[TBL] [Abstract][Full Text] [Related]
36. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
37. Potentiation of morphine-induced mechanical antinociception by σ₁ receptor inhibition: role of peripheral σ₁ receptors.
Sánchez-Fernández C; Nieto FR; González-Cano R; Artacho-Cordón A; Romero L; Montilla-García Á; Zamanillo D; Baeyens JM; Entrena JM; Cobos EJ
Neuropharmacology; 2013 Jul; 70():348-58. PubMed ID: 23524304
[TBL] [Abstract][Full Text] [Related]
38. Intrathecally injected morphine inhibits inflammatory paw edema: the involvement of nitric oxide and cyclic-guanosine monophosphate.
Brock SC; Tonussi CR
Anesth Analg; 2008 Mar; 106(3):965-71, table of contents. PubMed ID: 18292447
[TBL] [Abstract][Full Text] [Related]
39. LiCl uncouples signal transduction in morphine-induced supraspinal antinociception in mice.
Raffa RB; Martinez RP; Renzi MJ; Codd EE
Gen Pharmacol; 1995 Mar; 26(2):317-20. PubMed ID: 7590080
[TBL] [Abstract][Full Text] [Related]
40. Effects of acute and chronic administration of L-arginine on the antinociceptive action of morphine-6-beta-D-glucuronide.
Bhargava HN; Bian JT
Pharmacology; 1997 Oct; 55(4):165-72. PubMed ID: 9396075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
